Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."

TSX:MSL - Post Discussion

MERUS LABS INTERNATIONAL INC > Not much is happening...
View:
Post by Mazz889 on Apr 05, 2017 3:06pm

Not much is happening...

Not much has been happening in the past couple of months... Is this stock doomed to stay where it is at? What do you all think?
Comment by Kensin1953 on Apr 05, 2017 5:57pm
The math said sideways for a few months. It's down as the only traders are those giving up. They have until the end of April to make something happen or it will fade away to about $.75c cdn. Most of the larger traders have their positions about 20 mil shares bought since Nevember 2016 under $1.28cdn   Would not be surprised to see a rally to $1.45 on news however it seems it will be ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities